Gracell Biotechnologies Inc. announced that the management team will participate in and attend one-on-one meetings at three investor conferences in September 2022 as follows.
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three investor conferences in September 2022 as follows:
Citi Hong Kong China Corporate Day – Virtual
One-on-one meetings: Tuesday, September 20, 2022 – Wednesday, September 21, 2022
Cantor Oncology, Hematology & HemeOnc Conference
Panel Presentation: Wednesday, September 28 at 4:15 p.m. ET
One-on-one meetings: Wednesday, September 28, 2022
Location: New York, NY
Jefferies Cell & Genetic Medicine Summit
Fireside Chat: Friday, September 30 at 2:00 p.m. ET
One-on-one meetings: Friday, September 30, 2022
Location: New York, NY
A webcast of the fireside chat will be available on the News and Events section of Gracell’s investor website. A replay of the webcast will be available for 30 days following the event.
About Gracell
Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CARTTM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com and follow @GracellBio on LinkedIn.
Media contact
Marvin Tang
marvin.tang@gracellbio.com
Investor contact
Gracie Tong
gracie.tong@gracellbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-participate-in-three-upcoming-investor-conferences-301623784.html
SOURCE Gracell Biotechnologies Inc.
Company Codes: NASDAQ-NMS:GRCL
